

A 1  
1. (Amended) A method of treating or inhibiting thrombosis in a subject comprising administering a composition comprising an effective amount of a PSGL-1 protein to the subject.

A 2  
2. (Amended) The method of claim 1, wherein the PSGL-1 protein is a soluble PSGL-1 protein or a fragment thereof, capable of treating or inhibiting thrombosis.

A 3  
8. (Amended) The method of claim 2, wherein the soluble PSGL-1 protein comprises an extracellular domain of human PSGL-1 protein or a fragment thereof, capable of treating or inhibiting thrombosis.

A 4  
17. (Amended) The method of claim 1, wherein the PSGL-1 protein is administered to the subject prior to thrombus formation.

A 5  
23. (Amended) A method for increasing the movement of cells relative to blood vessels in a subject comprising administering a composition comprising an effective amount of soluble PSGL-1 protein or a fragment thereof, and allowing the PSGL-1 protein or fragment thereof to treat or inhibit thrombosis, thereby increasing the movement of cells relative to blood vessels.

A 6  
25. (Amended) A method for inhibiting thrombus formation induced by a thrombus-inducing agent in a subject comprising administering a composition comprising an effective amount of soluble PSGL-1 protein or a fragment thereof, wherein the PSGL-1 protein or fragment is capable of treating or inhibiting thrombosis.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com